11/6/2026

Janusmed sex and gender

Janusmed sex and gender – daridorexant hydrochloride

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Daridorexant

Daridorexant

Class : A

Show all info

Print

Contact us

  1. QUVIVIQ (daridorexant). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2026-03-12, cited 2026-10-07]

  2. Zeng LN, Zong QQ, Yang Y, Zhang L, Xiang YF, Ng CH et al. Gender Difference in the Prevalence of Insomnia: A Meta-Analysis of Observational Studies. Front Psychiatry. 2020;11:577429.

  3. Muehlan C, Brooks S, Zuiker R, van Gerven J, Dingemanse J. Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration. Eur Neuropsychopharmacol. 2019;29(7):847-857.

  4. Mignot E, Mayleben D, Fietze I, Leger D, Zammit G, Bassetti CLA et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022;21(2):125-139.

  5. Jiang M, Li H, Kong L. Data mining and safety analysis of dual orexin receptor antagonists (DORAs): a real-world pharmacovigilance study based on the FAERS database. Front Pharmacol. 2024;15:1436405.

  6. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]

  1. QUVIVIQ (daridorexant). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2026-03-12, cited 2026-10-07]
  2. Zeng LN, Zong QQ, Yang Y, Zhang L, Xiang YF, Ng CH et al. Gender Difference in the Prevalence of Insomnia: A Meta-Analysis of Observational Studies. Front Psychiatry. 2020;11:577429.
  3. Muehlan C, Brooks S, Zuiker R, van Gerven J, Dingemanse J. Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration. Eur Neuropsychopharmacol. 2019;29(7):847-857.
  4. Mignot E, Mayleben D, Fietze I, Leger D, Zammit G, Bassetti CLA et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022;21(2):125-139.
  5. Jiang M, Li H, Kong L. Data mining and safety analysis of dual orexin receptor antagonists (DORAs): a real-world pharmacovigilance study based on the FAERS database. Front Pharmacol. 2024;15:1436405.
  6. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]